Skip to content

The Enhancement of the neoadjuvant Chemotherapy of Breast Cancer Combined Ultrasound and Microbubbles

The Enhancement of the neoadjuvant Chemotherapy of Breast Cancer Combined Ultrasound and Microbubbles

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010680
Enrollment
Unknown
Registered
2017-02-19
Start date
2016-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Experiemental group 1:neoadjuvant chemotherapy and B model with low mechanical index
Experiemental group 2:neoadjuvant chemotherapy and B model with high mechanical index
Experiemental group 3:neoadjuvant chemotherapy and VFlash model with low mechanical index
Experiemental group 4:neoadjuvant chemotherapy and VFlash model with high mechanical index

Sponsors

Xinqiao Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed breast cancer; (2) Female,aged 18 to 75 years; (3) Single acoustic accessible lesion evaluated by Ultrasound, Computed Tomography(CT) or Magnetic Resonance Imaging(MRI); (4) Expected survival time=5 months; Performance Status(PS) 0-2; (5) Blood routine examination: WBC=3.5?10^9/L; ANC=1.5?10^9/L; PLT=80?10^9/L; Hb=90g/L; (6) Hepatic and renal function test: ALTAST=2.5 times that of the upper limit of normal; UreaCrea=1.25 times that of the upper limit of normal; (7) No known symptoms of heart failure & respiratory function insufficiency; (8) No known previous malignant tumor history; (9) Good treatment compliance, no mental disorders; (10) Signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) During pregnancy or lactation; (2) Allergic to chemotherapy substances or allergic constitution; (3) With massive ascites; (4) Positive lung, brain, or other organs metastasis; (5) During therapeutic course of other anticancer drugs or radiotherapy; (6) Participating in other clinical trials, or less than 4 weeks since the accomplishment of previous chemotherapy;

Design outcomes

Primary

MeasureTime frame
To evaluate and compare the toxic effects and safety of the neoadjuvant Chemotherapy drugs in combination with US contrast agent under sonication with the neoadjuvant Chemotherapy drugs alone.;tumor size;

Countries

China

Contacts

Public ContactZHENG LIU

Xinqiao Hospital, Third Military Medical University

liuzhengs@163.com+86 13983406200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026